Skip to content
How It Works
Explore
Resources Ask a Question
Who It's For
Patients
Decode results, prep for appointments, weigh options.
Caregivers & advocates
Carry the research load for someone you love.
Providers & clinicians
Resources for patients in your practice.
Log In Ask a Question
PubMed This is a summary of 21 peer-reviewed journal articles Updated
Cardiology

The Science of the Heart: Biology, Genetics, and Diagnosis

At a Glance

Hypertrophic cardiomyopathy (HCM) is diagnosed when the heart wall thickness reaches 15mm or more. Echocardiograms and Cardiac MRIs are essential to measure this thickness, evaluate scar tissue (LGE), and monitor critical warning signs like a dropping ejection fraction (EF).

To understand Hypertrophic Cardiomyopathy (HCM), it helps to look under the hood of the heart at the microscopic level. HCM is not just a “thick heart”; it is a condition rooted in the very machinery that makes the heart beat.

The Biology: A Faulty Engine

The heart is made of millions of tiny units called sarcomeres. You can think of a sarcomere as a “molecular engine” that allows heart muscle cells to contract and relax [1].

In most people with HCM, a genetic mutation (often in the MYBPC3 or MYH7 genes) acts like a glitch in the engine’s blueprint [1][2]. This glitch causes the heart to become hypercontractile, meaning it pulls too hard and uses too much energy [3][4]. Over time, the heart tries to compensate for this inefficient, high-stress “engine” by growing thicker—much like a bicep grows larger when it is constantly lifting heavy weights [4][5]. This thickening is called hypertrophy [6].

Definitively Diagnosing HCM

Doctors use imaging and electrical tests to see if your heart meets the formal criteria for HCM.

  • The Electrocardiogram (ECG/EKG): This simple test measures the electrical activity of your heart. An abnormal ECG is often the very first clue that leads to an HCM diagnosis, as the thickened muscle changes how electrical signals travel. It is a standard part of routine surveillance [6][7].
  • Wall Thickness (The Gold Standard): A maximum left ventricular wall thickness of 15 millimeters (mm) or more on an imaging scan, which cannot be explained by other conditions like high blood pressure [6][8].
  • Family History: If a close relative has HCM, a thickness of 13 mm may be enough for a diagnosis [8].
  • In Children: Because children are smaller, doctors use “Z-scores” to adjust for body size rather than a flat 15 mm cutoff [9][10].

Echo vs. Cardiac MRI: Why You Need Both

While an Echocardiogram (ultrasound of the heart) is usually the first test, a Cardiac MRI (CMR) provides a much more detailed “map” of the heart [11][12].

Late Gadolinium Enhancement (LGE)

The most critical part of a Cardiac MRI is a technique called Late Gadolinium Enhancement (LGE). During the MRI, a contrast agent (gadolinium) is injected into your vein. In a healthy heart, this agent washes out quickly. However, it gets “stuck” in areas of the heart that have scarring or fibrosis [11][13].

  • Why it matters: Seeing these areas of LGE (scarring) helps doctors predict the risk of dangerous heart rhythms. Finding extensive scarring (often cited as more than 15% of the heart muscle) may lead your doctor to recommend a protective device like an ICD [14][15][16].

Checklist: Reading Your Imaging Report

When you receive your imaging report, look for these key terms and numbers to discuss with your cardiologist:

  1. Maximum Wall Thickness (MLVWT): Measured in millimeters (mm). This tells you how thick the thickest part of your heart is [6].
  2. LVOT Gradient: This measures how much the blood flow is being blocked as it leaves the heart. A resting gradient of 30 mmHg or higher indicates “obstructive” HCM [17].
  3. LGE Percentage: Only found on MRI reports. It indicates how much of the heart muscle has been replaced by scar tissue [14].
  4. Systolic Anterior Motion (SAM): This describes a specific movement of the mitral valve that often causes the “blockage” in obstructive HCM [18][19].
  5. Ejection Fraction (EF): This measures what percentage of blood leaves the heart with each beat. In early or stable HCM, this number is often “super-normal” (high), reflecting the hypercontractile nature of the heart. Important Warning: If you see your EF dropping—even into what is considered a “normal” range like 50%—this is not a sign that your heart is “getting better.” In HCM, a declining EF is a critical warning sign that the heart is becoming “burned-out” and progressing toward heart failure. You should discuss any drop in EF with your doctor immediately [3][20][21].

Understanding these technical details allows you to have a much more informed conversation with your medical team about your specific “phenotype” or how the disease is showing up in your body.

Return to Home

Common questions in this guide

What is the normal wall thickness for an HCM diagnosis?
Doctors typically look for a maximum left ventricular wall thickness of 15 millimeters or more. If you have a close family member with HCM, a thickness of 13 millimeters may be enough for a diagnosis.
Why do I need a Cardiac MRI if I already had an echocardiogram?
While an echocardiogram is a great first test, a Cardiac MRI provides a more detailed map of your heart. It can show Late Gadolinium Enhancement (LGE), which reveals areas of heart scarring that help doctors predict your risk for dangerous heart rhythms.
What does Late Gadolinium Enhancement (LGE) mean on my MRI report?
Late Gadolinium Enhancement indicates areas where scar tissue, or fibrosis, has formed in your heart muscle. Knowing how much scarring is present helps your cardiologist determine if you might need a protective device like an ICD.
What does my Ejection Fraction (EF) number mean in HCM?
In early HCM, the EF is often high because the heart is hypercontractile. If your EF starts to drop, even into a normally healthy range like 50 percent, it is a critical warning sign that the heart is becoming overworked and progressing toward heart failure.
What causes Hypertrophic Cardiomyopathy?
In most people, HCM is caused by a genetic mutation in the heart's cellular machinery, often in the MYBPC3 or MYH7 genes. This mutation causes the heart muscle to pull too hard, use too much energy, and thicken over time.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.Is my wall thickness at 15mm or above, and is the thickening 'asymmetric' or 'concentric'?
  2. 2.What was the exact percentage of 'Late Gadolinium Enhancement' found on my MRI, and how does that influence my risk profile?
  3. 3.Did my echocardiogram show 'Systolic Anterior Motion' (SAM) of the mitral valve?
  4. 4.Was my LVOT gradient measured during a 'Valsalva maneuver' or exercise, and what were those numbers?
  5. 5.If a genetic mutation was found, is it a 'truncating' mutation in the MYBPC3 gene, and what does that mean for my long-term outlook?

Questions For You

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

References

References (21)
  1. 1

    Hypertrophic cardiomyopathy: diagnosis and therapeutic options.

    Gluckman TJ

    The American journal of managed care 2021; (27(6 Suppl)):S111-S117 doi:10.37765/ajmc.2021.88628.

    PMID: 33861535
  2. 2

    Hypertrophic cardiomyopathy clinical phenotype is independent of gene mutation and mutation dosage.

    Viswanathan SK, Sanders HK, McNamara JW, et al.

    PloS one 2017; (12(11)):e0187948 doi:10.1371/journal.pone.0187948.

    PMID: 29121657
  3. 3

    Modulating myosin function to treat hypertrophic cardiomyopathy.

    Fernández-Ruiz I

    Nature reviews. Cardiology 2019; (16(4)):201 doi:10.1038/s41569-019-0170-9.

    PMID: 30755739
  4. 4

    Interplay of Genotype and Substrate Stiffness in Driving the Hypertrophic Cardiomyopathy Phenotype in iPSC-Micro-Heart Muscle Arrays.

    Guo J, Jiang H, Oguntuyo K, et al.

    Cellular and molecular bioengineering 2021; (14(5)):409-425 doi:10.1007/s12195-021-00684-x.

    PMID: 34777601
  5. 5

    Mechanical Resistance to Micro-Heart Tissue Contractility unveils early Structural and Functional Pathology in iPSC Models of Hypertrophic Cardiomyopathy.

    Guo J, Jiang H, Schuftan D, et al.

    bioRxiv : the preprint server for biology 2023; doi:10.1101/2023.10.30.564856.

    PMID: 37961198
  6. 6

    Frequency of misdiagnosis in hypertrophic cardiomyopathy.

    Nielsen SK, Rasmussen TB, Hey TM, et al.

    European heart journal. Quality of care & clinical outcomes 2025; (11(2)):105-112 doi:10.1093/ehjqcco/qcae031.

    PMID: 38664062
  7. 7

    Cardiac troponin I is associated with non-sustained ventricular tachycardia in patients with hypertrophic obstructive cardiomyopathy.

    Zhou Y, Yu M, Yuan J, et al.

    Heart and vessels 2020; (35(6)):876-885 doi:10.1007/s00380-019-01549-0.

    PMID: 31907598
  8. 8

    Cardiology: hypertrophic cardiomyopathy.

    , Firth J

    Clinical medicine (London, England) 2019; (19(1)):61-63 doi:10.7861/clinmedicine.19-1-61.

    PMID: 30651247
  9. 9

    Distinguishing left ventricular hypertrophy from hypertrophic cardiomyopathy in adolescents: a longitudinal observation study.

    Forså MI, Smedsrud MK, Haugaa KH, et al.

    European journal of preventive cardiology 2024; (31(5)):591-598 doi:10.1093/eurjpc/zwad361.

    PMID: 37992187
  10. 10

    Yield of Clinical Screening for Hypertrophic Cardiomyopathy in Child First-Degree Relatives.

    Norrish G, Jager J, Field E, et al.

    Circulation 2019; (140(3)):184-192 doi:10.1161/CIRCULATIONAHA.118.038846.

    PMID: 31006259
  11. 11

    The Hypertrophic Cardiomyopathy Phenotype Viewed Through the Prism of Multimodality Imaging: Clinical and Etiologic Implications.

    Rowin EJ, Maron BJ, Maron MS

    JACC. Cardiovascular imaging 2020; (13(9)):2002-2016 doi:10.1016/j.jcmg.2019.09.020.

    PMID: 31864978
  12. 12

    Multimodality imaging of hypertrophic cardiomyopathy.

    Dong T, Gilliland Y, Kramer CM, et al.

    Progress in cardiovascular diseases 2023; (80()):14-24 doi:10.1016/j.pcad.2023.08.004.

    PMID: 37586654
  13. 13

    Late Gadolinium Enhancement and Electrocardiographic Associations in Hypertrophic Cardiomyopathy.

    Asfour I, Karim S, Tabraiz SA, et al.

    Annals of noninvasive electrocardiology : the official journal of the International Society for Holter and Noninvasive Electrocardiology, Inc 2025; (30(4)):e70077 doi:10.1111/anec.70077.

    PMID: 40464065
  14. 14

    Predictors of sudden cardiac death in postmyectomy hypertrophic cardiomyopathy with obstruction.

    Zhu C, Yang S, Zhao K, et al.

    Heart rhythm 2026; (23(5)):1196-1203 doi:10.1016/j.hrthm.2025.05.008.

    PMID: 40368289
  15. 15

    Myocardial tissue characterization by gadolinium-enhanced cardiac magnetic resonance imaging for risk stratification of adverse events in hypertrophic cardiomyopathy.

    Raiker N, Vullaganti S, Collins JD, et al.

    The international journal of cardiovascular imaging 2020; (36(6)):1147-1156 doi:10.1007/s10554-020-01808-6.

    PMID: 32166506
  16. 16

    Left ventricular involvement assessed by LGE-CMR in predicting the risk of adverse outcomes of arrhythmogenic cardiomyopathy with ICDs.

    Zhang N, Song Y, Hua W, et al.

    International journal of cardiology 2021; (337()):79-85 doi:10.1016/j.ijcard.2021.04.015.

    PMID: 33839174
  17. 17

    Hypertrophic obstructive cardiomyopathy.

    Veselka J, Anavekar NS, Charron P

    Lancet (London, England) 2017; (389(10075)):1253-1267 doi:10.1016/S0140-6736(16)31321-6.

    PMID: 27912983
  18. 18

    Mitral valve and papillary muscle abnormalities in hypertrophic obstructive cardiomyopathy.

    Teo EP, Teoh JG, Hung J

    Current opinion in cardiology 2015; (30(5)):475-82 doi:10.1097/HCO.0000000000000200.

    PMID: 26192489
  19. 19

    Mitral Valve Disease in Hypertrophic Cardiomyopathy:Evaluation and Management.

    Jain CC, Newman DB, Geske JB

    Current cardiology reports 2019; (21(11)):136 doi:10.1007/s11886-019-1231-8.

    PMID: 31673812
  20. 20

    Conduction block and thin and hypokinetic myocardial segments in feline hypertrophic cardiomyopathy.

    Sung Y, Park J, Chae Y, et al.

    Veterinarni medicina 2025; (70(8)):302-306 doi:10.17221/14/2025-VETMED.

    PMID: 40995508
  21. 21

    Genotype-phenotype associations in sarcomeric hypertrophic cardiomyopathy associated with mutations in the MYBPC3 gene: Systematic review and meta-analysis.

    Nogueira-Garcia B, Pinheiro D, Gregório C, et al.

    Journal of cardiology 2026; (87(3)):205-211 doi:10.1016/j.jjcc.2025.12.007.

    PMID: 41407035

This page explains Hypertrophic Cardiomyopathy (HCM) biology and imaging terminology for educational purposes only. Always consult your cardiologist to interpret your specific echocardiogram or MRI results.

Get notified when new evidence is published on Hypertrophic Cardiomyopathy.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.